Kilitch Drugs (India) share news, announcements and annual reports
NSE: KILITCHBSE: 524500Pharmaceuticals & BiotechnologySmall Cap
Kilitch Drugs (India) Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1994 on BSE, Sep 2010 on NSE
Last close ₹201.32down ₹7.82 (3.74%)BSE ₹201.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹209.14.
30 Oct: open ₹211.45, high ₹212.24, low ₹200.25
52-week range of traded prices to 30 Oct 2026
₹117.25Low, 30 Mar 2026₹267.90High, 7 Oct 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹704 Cr1,776th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 23.42
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.52
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 12.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 8.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.32
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 34,67341.3% delivered
Kilitch Drugs (India) share news and announcements
491 announcements, routine notices left out, newest first. Page 7 of 10.
Aug 2018
13 Aug · Results
13 Aug · Board meeting
Jun 2018
28 Jun · Board meeting
May 2018
29 May · Legal
Exchange has sought clarification from Kilitch Drugs (India) Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone Reconciliation of Equity not submitted -2. Consolidated Reconciliation of Equity not submitted The response of the Company is awaited.25 May · Board meeting
25 May · Results
17 May · Board meeting
Apr 2018
Mar 2018
31 Mar · Board meeting
16 Mar · Board meeting
13 Mar · Board meeting
Feb 2018
14 Feb · Board meeting
14 Feb · Results
Dec 2017
Nov 2017
14 Nov · Board meeting
14 Nov · Results
Oct 2017
Sep 2017
29 Sep · Meeting
21 Sep · Legal
Exchange has sought clarification from Kilitch Drugs (India) Limited with respect to announcement dated 20-Sep-2017, regarding "Outcome of Board Meeting held on September 20, 2017. The board of directors of the company have hereby approved the allotment of 2100000 warrants on preferential basis and have appointed Ms. Jill Gada, as the company secretary w.e.f. September 20, 2017.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.15 Sep · Board meeting
Aug 2017
24 Aug · Legal
Exchange has sought clarification from Kilitch Drugs (India) Limited with respect to announcement dated 23-Aug-2017, regarding "Outcome of Board Meeting held on August 23, 2017.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.23 Aug · Board meeting
14 Aug · Results
14 Aug · Board meeting
2 Aug · Meeting
Jul 2017
25 Jul · Board meeting